Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager for prostate cancer.
- Home |
- ‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
- February 23, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
